新一代经导管主动脉瓣植入器械术后起搏器植入率的系统综述
新一代器械PPI率在2.3%至36.1%间波动;自膨胀瓣膜(尤其早期CoreValve及新一代Evolut R)PPI率高于球囊扩张瓣膜;女性、既存传导异常、左室流出道钙化、球囊预扩张及植入深度与PPI风险增加相关。
要点
- 新一代TAVI器械术后PPI率变异大(2.3%-36.1%),自膨胀瓣膜PPI率普遍高于球囊扩张瓣膜。
- 既存传导异常、左室流出道钙化、球囊预扩张及植入深度增加PPI风险。
- PPI率最高五分位组女性比例显著高于最低五分位组(50.9% vs 46.3%,P<0.001)。
核心结论
- 新一代TAVI器械术后PPI率高度变异,需根据瓣膜类型、既存传导异常及解剖因素制定个体化植入策略以降低PPI风险。
主要发现
- 新一代TAVI器械术后PPI率范围为2.3%至36.1%。
- 球囊扩张瓣膜:早期SAPIEN器械PPI率2.3%-28.2%,新一代SAPIEN 3为4.0%-24.0%。
- 自膨胀瓣膜:早期CoreValve器械PPI率16.3%-37.7%,新一代Evolut R为14.7%-26.7%。
- PPI率最高五分位(>26.0%)组女性比例高于最低五分位(<12.1%)组(50.9% vs 46.3%,P<0.001)。
- 既存传导异常(电学因素)、左室流出道钙化(解剖因素)、球囊瓣膜成形及植入深度(操作因素)与PPI风险增加相关。
关键数值与推荐
- PPI率最高五分位定义为>26.0%,最低五分位定义为<12.1%。
- 女性在最高五分位组占比50.9%,最低五分位组占比46.3%(P<0.001)。
临床怎么用
- 临床选择TAVI瓣膜时需综合考虑瓣膜类型、既存传导异常及解剖因素(如左室流出道钙化)以评估PPI风险。
- 对于高PPI风险患者(如女性、既存传导异常、左室流出道钙化),应优化操作(如避免过深植入、谨慎球囊预扩张)并加强术后监测。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) with new-generation prostheses remains debated. This systematic review analyses the incidence of PPI after TAVI with new-generation devices and evaluates the electrical, anatomical, and procedural factors associated with PPI. In addition, the incidence of PPI after TAVI with early generation prostheses was reviewed for comparison. METHODS AND RESULTS: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist, this systematic review screened original articles published between October 2010 and October 2017, reporting on the incidence of PPI after implantation of early and new-generation TAVI prostheses. Of the 1406 original articles identified in the first search for new-generation TAVI devices, 348 articles were examined for full text, and finally, 40 studies (n = 17 139) were included. The incidence of a PPI after the use of a new-generation TAVI prosthesis ranged between 2.3% and 36.1%. For balloon-expandable prostheses, the PPI rate remained low when using an early generation SAPIEN device (ranging between 2.3% and 28.2%), and with the new-generation SAPIEN 3 device, the PPI rate was between 4.0% and 24.0%. For self-expandable prostheses, the PPI rates were higher with the early generation CoreValve device (16.3-37.7%), and despite a reduction in PPI rates with the new Evolut R, the rates remained relatively higher (14.7-26.7%). When dividing the studies according to the highest (>26.0%) and the lowest (<12.1%) quintile of PPI rate, patients within the highest quintile were more frequently women when compared with the lowest quintile group (50.9% vs. 46.3%, P < 0.001). Pre-existent conduction abnormalities (electrical factor), calcification of the left ventricular outflow tract (anatomical factor), and balloon valvuloplasty and depth of implantation (procedural factors) were associated with increased risk of PPI. CONCLUSION: The rate of PPI after TAVI with new-generation devices is highly variable. Specific recommendations for implantation of each prosthesis, taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors, may be needed to reduce the risk of PPI.
引用
- van Rosendael PJ, Delgado V, Bax JJ, et al. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J. 2018. PMID: 29420704. doi:10.1093/eurheartj/ehx785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。